Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials

Jiajia Ma; Zi Liu; Jitao Wu; Zhongbao Zhou; Xuebao Zhang; Yuanshan Cui; Chunhua Lin

doi:10.21037/tau-19-809

Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials

Transl Androl Urol. 2020 Jun;9(3):1405-1414. doi: 10.21037/tau-19-809.

Authors

Jiajia Ma¹, Zi Liu^{1

2}, Jitao Wu¹, Zhongbao Zhou^{1

2}, Xuebao Zhang¹, Yuanshan Cui¹, Chunhua Lin¹

Affiliations

¹ Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
² Binzhou Medical University, Yantai, China.

Abstract

This meta-analysis was performed to assess the efficacy and safety of taking tadalafil 5 mg once-daily for at least 6 months in the treatment of erectile dysfunction (ED). Based on databases: MEDLINE, EMBASE and Cochrane Controlled Trials Register, this analysis was performed to collect randomized controlled trials (RCTs) of tadalafil 5mg once-daily in treating ED over 6 months. Reviewers also investigated the references of each literature. The meta-analysis covered a total of 1,596 patients in six RCTs. The tadalafil group performed a better effect in terms of the international index of erectile function-erectile function (IIEF) domain (P=0.005) for the treatment of ED compared with the placebo group. Safety assessments including discontinuations due to adverse events (AEs) (P=0.31) and treatment-emergent AEs (P=0.06) indicated that the tadalafil group had a better tolerate. The analysis elucidates that the dose of 5 mg per day of tadalafil showed a good effect after the treatment of at least 6 months relative to the control group with fewer side effects.

Keywords: Randomized controlled trial; Tadalafil; erectile dysfunction (ED); once-daily.

Publication types

Review